Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026

The U.S. Food & Drug Administration (FDA) on Tuesday extended review for Ascendis Pharma A/S‘ (NASDAQ:ASND) New Drug Application (NDA) for TransCon CNP (navepegritide) for children with achondroplasia. • ASND is in positive territory. Check the fundamentals here.Achondroplasia is a genetic disorder causing dwarfism, characterized by short limbs, a normal-sized torso, and a large head.It is the most common form of skeletal dysplasia and results from a mutation in the FGFR3 gene, which impairs cartilage from ...